LINC01124: A Potential Drug Target and Biomarker for Diseases

Target Name: LINC01124

NCBI ID: G440925

LINC01124

Other Name(s): long intergenic non-protein coding RNA 1124 | Long intergenic non-protein coding RNA 1124

LINC01124: A Potential Drug Target and Biomarker for Diseases

LINC01124 is a long intergenic non-protein coding RNA (lncRNA) with a length of approximately 292 nucleotides. It is located within the gene cluster onchr36.810 and has a 5'-end tag UTR3' and a 3'-end tag UTG1.

LINC01124 is a non-coding RNA molecule that is involved in the regulation of gene expression. It is expressed in a variety of tissues and cells throughout the body, including the brain, heart, and liver. It is also highly expressed in the placenta, which supports the hypothesis that it may play a role in fetal development and growth.

Recent studies have identified LINC01124 as a potential drug target and biomarker for several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases.

One of the reasons for the potential drug targeting of LINC01124 is its unique structure and expression pattern. As a lncRNA, it is not a protein, which means it is not subject to the same biochemical and cellular stressors as proteins. This allows LINC01124 to be stable and to function as a non-coding RNA molecule for a longer period of time than proteins.

Another reason for the potential drug targeting of LINC01124 is its involvement in several disease-related processes. For example, LINC01124 has been shown to be involved in the regulation of cell adhesion, which is a critical process for the development and maintenance of tissues and organs. It has also been shown to be involved in the regulation of cell lifespan, which is important for the development and aging of tissues and organs.

In addition to its potential role in disease processes, LINC01124 also has potential as a biomarker. Its expression is highly correlated with several diseases, including cancer, neurodegenerative diseases, and cardiovascular diseases. This makes it a promising candidate for use as a biomarker for these diseases.

One of the challenges in studying LINC01124 is its complex expression pattern. As a lncRNA, it is expressed in a variety of tissues and cells throughout the body, making it difficult to identify and study its effects. Additionally, the functions of LINC01124 are not well understood, which can make it difficult to predict its effects on disease.

Despite these challenges, recent studies have identified several potential functions for LINC01124. For example, studies have shown that LINC01124 is involved in the regulation of cell adhesion, cell lifespan, and transcriptional factor activity. Additionally, LINC01124 has been shown to play a role in the regulation of cellular processes, such as cell division and apoptosis.

In conclusion, LINC01124 is a long intergenic non-protein coding RNA that is involved in the regulation of gene expression and has been identified as a potential drug target and biomarker for several diseases. Further research is needed to fully understand its functions and to develop effective therapies based on its potential.

Protein Name: Long Intergenic Non-protein Coding RNA 1124

The "LINC01124 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01124 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets